Literature DB >> 12150893

Memory CD8(+) T cells undergo peripheral tolerance.

Huub T C Kreuwel1, Sandra Aung, Cheryl Silao, Linda A Sherman.   

Abstract

Memory T cells differ from naive T cells in that they respond more rapidly and in greater numbers. In addition, memory T cells are generally believed to be less susceptible to tolerance induction than naive T cells. In this study, we show that this is not the case. Using two different methods of tolerance induction, peptide-induced tolerance and crosstolerance, we present evidence that memory CD8(+) T cells are as susceptible to tolerance as naive cells. These results have a direct impact on manipulating T cell responses to self-antigens in order to improve immunotherapy of cancer and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150893     DOI: 10.1016/s1074-7613(02)00337-0

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  22 in total

1.  CD62L- memory T cells enhance T-cell regeneration after allogeneic stem cell transplantation by eliminating host resistance in mice.

Authors:  Jifeng Zhang; Brice E Barefoot; Wenjian Mo; Divino Deoliveira; Jessica Son; Xiuyu Cui; Elizabeth Ramsburg; Benny J Chen
Journal:  Blood       Date:  2012-05-17       Impact factor: 22.113

2.  T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-gamma expression.

Authors:  Meixiao Long; Aaron M Slaiby; Adam T Hagymasi; Marianne A Mihalyo; Alexander C Lichtler; Steven L Reiner; Adam J Adler
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

3.  Tolerization of an established alphaB-crystallin-reactive T-cell response by intravenous antigen.

Authors:  Richard Verbeek; Koen van der Mark; Eric F Wawrousek; Arianne C Plomp; Johannes M van Noort
Journal:  Immunology       Date:  2007-04-26       Impact factor: 7.397

4.  Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen.

Authors:  Amy D Higgins; Marianne A Mihalyo; Adam J Adler
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

Review 5.  Role of T cells and dendritic cells in glomerular immunopathology.

Authors:  Christian Kurts; Felix Heymann; Veronika Lukacs-Kornek; Peter Boor; Jürgen Floege
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

6.  Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma.

Authors:  Ihid C Leao; Priya Ganesan; Todd D Armstrong; Elizabeth M Jaffee
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

7.  Distinct mechanisms mediate naive and memory CD8 T-cell tolerance.

Authors:  Evan R Jellison; Michael J Turner; David A Blair; Elizabeth G Lingenheld; Li Zu; Lynn Puddington; Leo Lefrançois
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

8.  Inhibition of recall responses through complementary therapies targeting CD8+ T-cell- and alloantibody-dependent allocytotoxicity in sensitized transplant recipients.

Authors:  Jason M Zimmerer; Phillip H Horne; Lori A Fiessinger; Mason G Fisher; Kartika Jayashankar; Sierra F Garcia; Mahmoud Abdel-Rasoul; Nico van Rooijen; Ginny L Bumgardner
Journal:  Cell Transplant       Date:  2012-10-11       Impact factor: 4.064

9.  In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.

Authors:  Marianne A Mihalyo; Amy D H Doody; Jeremy P McAleer; Elizabeth C Nowak; Meixiao Long; Yi Yang; Adam J Adler
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

10.  Antigen-driven effector CD8 T cell function regulated by T-bet.

Authors:  Brandon M Sullivan; Amy Juedes; Susanne J Szabo; Matthias von Herrath; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.